Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Helus Pharma reports before market open, meaning Day 0 captures the first full trading session where the market reacts to results, while Day +1 reflects follow-through action.

Helus Pharma has exhibited volatile post-earnings price action, with an average absolute Day 0 move of 4.76% and Day +1 move of 4.65%. The most dramatic reaction came in November 2024, when the stock plunged 10.26% on earnings day, followed by a 4.76% rebound the next session. More recently, the August 2026 report triggered a 4.72% Day 0 gain but gave back ground with a 3.50% decline on Day +1.

The February 2026 earnings showed a more muted initial reaction (2.87% Day 0 gain) but delivered a substantial 11.00% surge on Day +1, suggesting positive sentiment built as investors digested the results. The trading ranges have been wide, averaging 7.31% on Day 0 and 7.45% on Day +1, reflecting the high volatility typical of clinical-stage biotech stocks where sentiment can shift rapidly on pipeline updates or cash burn commentary.

The directional pattern is mixed, with no clear bias toward gains or losses, indicating that stock performance is highly dependent on the specific content of each earnings release rather than a predictable seasonal pattern. Investors should prepare for significant intraday swings in either direction.

Part 2.2: Options Market Expected Move

The options market is pricing in a 31.41% expected move for the November 20, 2026 expiration, implying a range between $6.44 and $12.34. This expected move is substantially larger than the stock's average historical Day 0 move of 4.76% and even exceeds the average Day 0 trading range of 7.31%. The elevated options pricing suggests heightened uncertainty around this particular earnings event, likely reflecting the proximity to the anticipated Q4 2026 HLP003 Phase 3 data readout and the potential for material pipeline updates that could significantly impact valuation.

Part 3: What Analysts Are Saying

Helus Pharma commands strong bullish sentiment from Wall Street analysts, with 10 Strong Buy ratings, zero Moderate Buys, 1 Hold, and no Sell ratings among the 11 analysts covering the stock. The average recommendation of 4.82 sits firmly in Strong Buy territory, and this consensus has remained unchanged over the past month, indicating stable conviction despite recent stock weakness.

The average price target of $41.20 implies substantial upside of 339% from the current price of $9.39, with estimates ranging from a low of $15.00 to a high of $70.00. The wide target range reflects differing assumptions about the probability of clinical success and commercial potential for HLP003 and HLP004.

The overwhelmingly bullish stance reflects analyst confidence in the company's clinical programs, particularly the FDA Breakthrough Therapy Designation for HLP003 and the upcoming Phase 3 data readout. The lack of any downgrades or negative revisions over the past month suggests analysts view the current valuation as attractive relative to the potential value creation if the Phase 3 trials succeed. However, the single Hold rating serves as a reminder that clinical-stage biotechs carry binary risk, and the path to commercialization remains uncertain despite the promising early data and regulatory support.

Part 4: Technical Picture

The Barchart Technical Opinion currently registers a Buy signal at 8%, down sharply from 24% one week ago and 56% one month ago, indicating rapidly deteriorating technical momentum heading into earnings. This dramatic weakening suggests the stock has lost significant technical support in recent weeks.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative, with selling pressure dominating recent sessions
• Medium-term (50% Buy): Neutral-to-positive reading suggests the intermediate trend remains constructive despite recent weakness
• Long-term (50% Buy): Moderate buy signal reflects relative strength in the longer-term trend, with the stock still above its 200-day moving average

The trend is characterized as Weak in strength and Weakest in direction, painting a picture of a stock losing momentum at a critical juncture. This deteriorating technical setup adds risk heading into an earnings event that could already trigger significant volatility.

From a moving average perspective, HELP trades above its 5-day ($9.04) and 10-day ($9.30) averages, indicating very short-term resilience, but sits below its 20-day ($9.97), 50-day ($11.36), and 100-day ($10.15) moving averages, confirming the intermediate-term downtrend. The stock remains above its 200-day moving average of $7.77, providing a key long-term support level.

The technical picture heading into earnings is cautionary. The stock has lost critical intermediate-term support levels and momentum indicators are flashing warning signs. The 50-day moving average at $11.36 represents overhead resistance, while the 200-day at $7.77 marks a crucial support zone. Given the weak technical setup combined with the options market pricing in a 31% move, traders should expect heightened volatility. A positive earnings surprise or encouraging pipeline commentary could trigger a sharp reversal back toward the 20-day average, while disappointment could test the 200-day support. The conflicting signals—short-term stability versus intermediate-term weakness—suggest the stock is coiled for a significant directional move once earnings clarity arrives.